Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-Vibrio cholerae lipopolysaccharide responses in mice.
暂无分享,去创建一个
S. Calderwood | F. Qadri | E. Ryan | P. Kováč | R. Saksena | A. Sheikh | M. M. Alam | A. Kalsy | J. Rollenhagen
[1] T. Wade,et al. Variable gene family usage of protective and non‐protective anti‐Vibrio cholerae O1 LPS antibody heavy chains , 2008, Microbiology and immunology.
[2] Firdausi Qadri,et al. Susceptibility to Vibrio cholerae Infection in a Cohort of Household Contacts of Patients with Cholera in Bangladesh , 2008, PLoS neglected tropical diseases.
[3] Shu-jie Hou,et al. Preparation of glycoconjugates by dialkyl squarate chemistry revisited. , 2008, Carbohydrate research.
[4] S. Calderwood,et al. Transcutaneous Immunization with Clostridium difficile Toxoid A Induces Systemic and Mucosal Immune Responses and Toxin A-Neutralizing Antibodies in Mice , 2007, Infection and Immunity.
[5] Mercedes Pascual,et al. Serotype cycles in cholera dynamics , 2006, Proceedings of the Royal Society B: Biological Sciences.
[6] J. Shiloach,et al. Immunogenicity of synthetic saccharide fragments of Vibrio cholerae O1 (Ogawa and Inaba) bound to Exotoxin A. , 2006, FEMS immunology and medical microbiology.
[7] S. Calderwood,et al. Transcutaneous Immunization with Toxin-Coregulated Pilin A Induces Protective Immunity against Vibrio cholerae O1 El Tor Challenge in Mice , 2006, Infection and Immunity.
[8] P. Kováč,et al. Length of the linker and the interval between immunizations influences the efficacy of Vibrio cholerae O1, Ogawa hexasaccharide neoglycoconjugates. , 2006, FEMS immunology and medical microbiology.
[9] David A. Sack,et al. Blood Group, Immunity, and Risk of Infection with Vibrio cholerae in an Area of Endemicity , 2005, Infection and Immunity.
[10] P. Kováč,et al. Effect of saccharide length on the immunogenicity of neoglycoconjugates from synthetic fragments of the O-SP of Vibrio cholerae O1, serotype Ogawa. , 2005, Carbohydrate research.
[11] R. Rappuoli,et al. Successful induction of protective antibody responses against Haemophilus influenzae type b and diphtheria after transcutaneous immunization with the glycoconjugate polyribosyl ribitol phosphate-cross-reacting material 197 vaccine. , 2004, The Journal of infectious diseases.
[12] M. Meeks,et al. Synthetic Fragments of Vibrio cholerae O1 Inaba O-Specific Polysaccharide Bound to a Protein Carrier Are Immunogenic in Mice but Do Not Induce Protective Antibodies , 2004, Infection and Immunity.
[13] A. Faruque,et al. Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh. , 2004, The Journal of infectious diseases.
[14] S. Calderwood,et al. Comparison of mucosal and systemic humoral immune responses after transcutaneous and oral immunization strategies. , 2002, Vaccine.
[15] P. Alzari,et al. Induction of protective immunity by synthetic Vibrio cholerae hexasaccharide derived from V. cholerae O1 Ogawa lipopolysaccharide bound to a protein carrier. , 2002, The Journal of infectious diseases.
[16] F. Nato,et al. Preparation, Immunogenicity, and Protective Efficacy, in a Murine Model, of a Conjugate Vaccine Composed of the Polysaccharide Moiety of the Lipopolysaccharide of Vibrio cholerae O139 Bound to Tetanus Toxoid , 2001, Infection and Immunity.
[17] P. Kováč,et al. Conjugating oligosaccharides to proteins by squaric acid diester chemistry: rapid monitoring of the progress of conjugation, and recovery of the unused ligand. , 2001, Carbohydrate research.
[18] C. Alving,et al. Transcutaneous Immunization with Bacterial ADP-Ribosylating Exotoxins, Subunits, and Unrelated Adjuvants , 2000, Infection and Immunity.
[19] S. Calderwood,et al. In Vitro and In Vivo Analyses of Constitutive and In Vivo-Induced Promoters in Attenuated Vaccine and Vector Strains ofVibrio cholerae , 2000, Infection and Immunity.
[20] S. Calderwood,et al. Optimizing the Germfree Mouse Model for In Vivo Evaluation of Oral Vibrio cholerae Vaccine and Vector Strains , 2000, Infection and Immunity.
[21] G. Matyas,et al. Transcutaneous Immunization with Bacterial ADP-Ribosylating Exotoxins as Antigens and Adjuvants , 1999, Infection and Immunity.
[22] C. Alving,et al. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. , 1998, Journal of immunology.
[23] David N. Taylor,et al. Phase 1 Evaluation of Vibrio choleraeO1, Serotype Inaba, Polysaccharide-Cholera Toxin Conjugates in Adult Volunteers , 1998, Infection and Immunity.
[24] G. Matyas,et al. Skin immunization made possible by cholera toxin , 1998, Nature.
[25] C. Wennerås,et al. Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1 , 1997, Infection and immunity.
[26] E. Ryan,et al. Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal antiamebic and anti-V. cholerae antibody responses in mice , 1997, Infection and immunity.
[27] S. Calderwood,et al. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain , 1997, Infection and immunity.
[28] M. Levine,et al. Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139: specificity and relevance to immunity , 1997, Clinical and diagnostic laboratory immunology.
[29] E. Ryan,et al. Development of a germfree mouse model of Vibrio cholerae infection , 1996, Infection and immunity.
[30] J. Holmgren,et al. Immune mechanisms and protective antigens of Vibrio cholerae serogroup O139 as a basis for vaccine development , 1996, Infection and immunity.
[31] J. Mekalanos,et al. Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo , 1993, Infection and immunity.
[32] Y. Haishima,et al. Occurrence of 2-O-methyl-N-(3-deoxy-L-glycero-tetronyl)-D-perosamine (4-amino-4,6-dideoxy-D-manno-pyranose) in lipopolysaccharide from Ogawa but not from Inaba O forms of O1 Vibrio cholerae. , 1993, Biochemical and biophysical research communications.
[33] R. Gupta,et al. Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin , 1992, Infection and immunity.
[34] R. Schneerson,et al. Persistence of serum antibodies elicited by Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants vaccinated at 3, 5 and 12 months of age. , 1991, The Pediatric infectious disease journal.
[35] R Weltzin,et al. New model for analysis of mucosal immunity: intestinal secretion of specific monoclonal immunoglobulin A from hybridoma tumors protects against Vibrio cholerae infection , 1991, Infection and immunity.
[36] J. Holmgren,et al. Vibrio cholerae expresses cell surface antigens during intestinal infection which are not expressed during in vitro culture , 1989, Infection and immunity.
[37] R. Glass,et al. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. , 1985, The Journal of infectious diseases.
[38] D. Sack,et al. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. , 1984, The Journal of infectious diseases.
[39] J. Holmgren,et al. Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid , 1976, Infection and immunity.
[40] W. Mosley,et al. Characteristics of the serum vibriocidal and agglutinating antibodies in cholera cases and in normal residents of the endemic and non-endemic cholera areas. , 1970, Journal of immunology.
[41] W. Mosley,et al. A serological survey for cholear antibodies in rural east Pakistan. 1. The distribution of antibody in the control population of a cholera-vaccine field-trial area and the relation of antibody titre to the pattern of endemic cholera. , 1968, Bulletin of the World Health Organization.
[42] W H Mosley,et al. A serological survey for cholera antibodies in rural east Pakistan. 2. A comparison of antibody titres in the innunized and control populationd of a cholera-vaccine field-trial area and the relation of antibody titre to cholera case rate. , 1968, Bulletin of the World Health Organization.
[43] R. F. Chen,et al. Removal of fatty acids from serum albumin by charcoal treatment. , 1967, The Journal of biological chemistry.